Navigation Links
Avipaxin Is First Entrant in Medical Arsenal for Neuro-Endocrine-Immune Connection(C) Product and Testing Protocols
Date:8/4/2009

OSCEOLA, Wis., Aug. 4 /PRNewswire/ -- NeuroScience, Inc. has launched a new product -- Avipaxin -- aimed at decreasing elevated levels of pro-inflammatory cytokines. Avipaxin supports acetylcholine levels by providing substrates for its production and by inhibiting its metabolizing enzyme, acetylcholinesterase. Initial studies at NeuroScience, Inc. revealed a significant decrease in pro-inflammatory cytokines and chemokines after Avipaxin use. These studies also revealed a decrease in the neurotransmitter norepinephrine and an increase in the neurotransmitter serotonin.

Historically, neurotransmitters, cytokines, and hormones were considered signal messengers of the Nervous, Endocrine, and Immune systems, respectively. However, recent evidence shows that those systems are actually part of a single and integrated Neuro-Endocrine-Immune (NEI) Connection(C).

Elevated pro-inflammatory cytokine levels lead to imbalances in neurotransmitter concentrations and raised hormone (cortisol) levels. Neurotransmitters are responsible for people's mood, concentration, sleep, and other mental and emotional functions. Cytokine-induced neurotransmitter imbalances are regularly noticed when people are sad, lethargic, and are unable to focus during an acute viral or bacterial infection. Serotonin, which was increased in the Avipaxin studies, is a particularly important neurotransmitter involved with mood and sleep. Research shows that persistent cytokine elevations lead to numerous physical and emotional symptoms that are difficult to manage.

Avipaxin modulates elevated cytokine levels by supporting acetylcholine-mediated signaling. The cholinergic anti-inflammatory pathway uses the neurotransmitter acetylcholine to down-regulate elevated pro-inflammatory cytokines. Decreasing pro-inflammatory cytokines leads to an indirect normalization of neurotransmitter levels, leading to a positive effect on mood, concentration, sleep, and other emotional and mental processes. Avipaxin should be considered for patients with suspected acute or persistent immune system activation.

Additional information regarding Avipaxin can be found at www.neurorelief.com/avipaxin.

About NeuroScience, Inc.:

NeuroScience, Inc, established in 1999, is devoted to medical solutions that improve health by providing novel laboratory assessments and products in the emerging field of NeuroEndocrine Immunology (NEI). The company is research and education-focused and has a database that includes results from over 300,000 patients.


'/>"/>
SOURCE NeuroScience, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. First biomarker discovered that predicts prostate cancer outcome
2. FDA Approves First Anti-Psychotic for Kids
3. Single-incision belly-button surgery to remove kidney performed first at UT Southwestern
4. First study examines newly-licensed RN work attitudes and intentions
5. Glades General Hospital First in Palm Beach County to Provide On-Site Electronic Birth Registration
6. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
7. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
8. High and mighty: first common height gene identified by researchers behind obesity gene finding
9. APA Comments on FDAs First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder
10. TriWest Creates First-of-its-Kind Partnership to Offer Military Leaders With Grief Support Program
11. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2017)... ... ... In any business, follow up is critical to success. It is the ... treatment, there will always be some patients who can’t or won’t make a immediate ... when it comes to presenting treatment. After the patient leaves, most practices end ...
(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs from biotech, pharmaceutical, ... and 31st at The Four Seasons Hotel Boston. , The Boston CEO ... offering exclusive access to key decision makers who influence deal making and investment. ...
(Date:5/26/2017)... ... May 26, 2017 , ... Boar’s Head ... bold recipes for Memorial Day entertaining that are sure to satisfy your guests’ ... fresh sliced meats and cheeses featured in these refreshingly balanced recipes are packed ...
(Date:5/26/2017)... ... May 26, 2017 , ... Silver Birch of Hammond, a new assisted ... more than four acres of land at 5620 Sohl Avenue in Hammond, serves older ... building includes 125 studio and one-bedroom apartments. Each of the private apartments at Silver ...
(Date:5/26/2017)... Colorado (PRWEB) , ... May 26, 2017 , ... ... will be this year’s recipient of proceeds from its 14th Annual Clays for ... 46700 E. County Road 30, Bennett, Colorado. , As part of BluSky’s ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... 10, 2017  The Corporate Whistleblower Center says, ... sleep therapy clinics to call us anytime at ... is involved in a substantial scheme to overbill ... from an employee of a medical equipment company ... to provide medical practice groups with extra generous incentives ...
(Date:5/9/2017)... , May 9, 2017  Oramed Pharmaceuticals ... ), a clinical-stage pharmaceutical company focused on the ... that the Canadian Intellectual Property Office has granted ... Oral Administration of Exenatide". The patent covers Oramed,s ... GLP-1 is an incretin hormone that ...
(Date:5/6/2017)... , May 5, 2017  May is Stroke ... one of the most important methods to prevent a ... the Centers for Disease Control and Prevention, undetected and ... 1 Omron, the global leader in personal heart ... the elimination of heart attack and stroke and is ...
Breaking Medicine Technology: